- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
FDA Approves Drug for New Use in Treatment of Psoriatic Arthritis
Washington--The Food and Drug Administration has approved Humira, a drug used to treat rheumatoid arthritis (RA), for additional use in the treatment of psoriatic arthritis, which is associated with psoriasis.
Washington--The Food and Drug Administration has approved Humira, a drug used to treat rheumatoid arthritis (RA), for additional use in the treatment of psoriatic arthritis, which is associated with psoriasis.
Humira blocks a protein called tumor necrosis factor alpha, or TNF-alpha, which is released by the immune system and causes joint swelling and other damage.
The FDA based its approval of the new use of Humira on a clinical trial involving 313 psoriatic arthritis patients who did not respond after being treated with anti- non-steroidal anti-inflammatory drugs.
The FDA also approved Humira for initial use in patients with moderate to severe (RA). Previously, it was approved for use only after other drug treatments failed.
